Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:31:58.421Z.
Calculation as of: 2026-10-06T17:31:58.421Z.
Quote observation: 2026-10-06T17:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$725.80M
Price/OCF Ratio
N/A
TTM Avg
4.41
3Y Avg
4.41
5Y Avg
4.41
Market Cap
$712.22M
Price/OCF Ratio
N/A
TTM Avg
24.89
3Y Avg
136.95
5Y Avg
245.47
Market Cap
$710.62M
Price/OCF Ratio
2.15
TTM Avg
4.78
3Y Avg
5.19
5Y Avg
6.02
Market Cap
$761.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$701.23M
Price/OCF Ratio
N/A
TTM Avg
1184.35
3Y Avg
1178.25
5Y Avg
1178.25
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $733.15M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $728.31M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $725.80M | N/A | 4.41 | 4.41 | 4.41 |
| Design Therapeutics, Inc. (DSGN)vs › | $746.36M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $712.22M | N/A | 24.89 | 136.95 | 245.47 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.62M | 2.15 | 4.78 | 5.19 | 6.02 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $761.20M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $765.00M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $701.23M | N/A | 1184.35 | 1178.25 | 1178.25 |
| Mesa Laboratories, Inc. (MLAB)vs › | $765.96M | 13.76 | 12.12 | 13.02 | 20.17 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
